Market reactionShares fell 11% on Nov 5.
Arbutus develops imdusiran and AB-101 for chronic hepatitis B and shares in lipid nanoparticle patent income; neither drug is approved.
Arbutus received about $178 million from Moderna's patent settlement in July and spent $230 million buying back 46 million shares at $5.00 in October. It has not reported its cash since. Imdusiran, an RNAi drug, helped 10 patients reach functional cure in Phase 2a combination trials, and FDA agreed a Phase 2b design, but no start date is set. FDA lifted the hold on AB-101, an oral PD-L1 inhibitor, in October. Another $1.3 billion depends on Moderna's appeal.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Imdusiran Phase 2b starts
Does Arbutus start the imdusiran Phase 2b, alone or with a partner?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Arbutus paid out $230 million; imdusiran's Phase 2b start and post-tender cash are unclear
Arbutus returns $230M to shareholders from Moderna settlement while imdusiran's Phase 2b hinges on post-tender cash sufficiency
LNP patent windfall funds a $230M capital return, but imdusiran's fate hinges on whether Arbutus rebuilds after gutting its own research
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Infectious diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.